Chinese Expert Consensus on Immunotherapy for Gynecological Malignant Tumors (2023 Edition)

Title: Chinese Expert Consensus on Immunotherapy for Gynecological Malignant Tumors (2023 Edition)
Edition: Original
Classification: Experts consensus
Field: Diagnosis and Treatment
Countries and regions: China
Guidelines users: Medical staff engaged in gynecological oncology work in clinical practice
Evidence classification method: This consensus adopts the following recommendation levels (Table 1), and for those without special instructions, the recommendation levels are all Class 2A. Table 1 Recommendation Levels and Their Representative Significance Recommendation level represents significance Class 1 is based on advanced clinical research evidence, with highly consistent expert opinions Class 2A is based on low-level clinical research evidence, with highly consistent expert opinions; Or based on advanced clinical research evidence, expert opinions are generally consistent Category 2B is based on low-level clinical research evidence, and expert opinions are generally consistent No matter what level of clinical research evidence is based on, there are obvious differences in expert opinions among the three categories
Development unit: Onco-Endocrinology Special Committee of China Anti Cancer Association
Registration time: 2023-05-31
Registration number: PREPARE-2023CN373
Purpose of the guideline: The Onco-Endocrinology Special Committee of China Anti Cancer Association led the organization of experts in the field of cancer. Based on high-level evidence-based clinical evidence, experts jointly discussed and voted to form the "Chinese Expert Consensus on Immunotherapy for Gynecological Malignant Tumors (2023 Edition)" for reference by domestic peers, in order to further standardize the clinical practice of immunotherapy for gynecological malignant tumors.